Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) and Johns Hopkins University have successfully submitted our proposal for a NIH Grant that will utilize CTT's patented technology as a smoking cessation ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

Bangalore: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval ...

The approval encompasses generic versions of Victoza for Type-2 Diabetes treatment and Saxenda for weight management.

Enjoy your very own urban adventure in open settings in Indian Bikes Driving 3D, an action game where you will have the chance to drive real motorbikes Indian Bikes Driving 3D is an action and ...

While all state Medicaid programs include GLP-1s prescribed for Type 2 diabetes, only 36 states cover at least one of the FDA-approved GLP-1s for obesity (Wegovy, Zepbound, or Saxenda).

While all state Medicaid programs include GLP-1s prescribed for Type 2 diabetes, only 36 states cover at least one of the FDA-approved GLP-1s for obesity (Wegovy, Zepbound, or Saxenda).

While all state Medicaid programs include GLP-1s prescribed for Type 2 diabetes, only 36 states cover at least one of the FDA-approved GLP-1s for obesity (Wegovy, Zepbound, or Saxenda).